Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Escalating Oral Doses of LY2393910 in Patients With Type 2 Diabetes Mellitus.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LY 2393910 (Primary)
Indications Type 2 diabetes mellitus
Focus Adverse reactions

Most Recent Events

09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
19 Apr 2011 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
24 Mar 2011 Planned end date changed from 1 Apr 2011 to 1 May 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com